Therapeutics News

Povidone-iodine 1.25% can be considered for the treatment of bacterial keratitis when antibiotic treatment is not practical, according to researchers in the American Journal of Ophthalmology.

Genentech announced positive results from the phase 3 trial, GiACTA, which evaluated Actemra in people with giant cell arteritis, according to a press release from the company.

BioLineRx Ltd. signed an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. for the in-licensing of a novel anti-inflammatory treatment for dry eye syndrome, according to a press release.

Most patients after trabeculectomy demonstrate relatively slow rates of visual field progression, similar to those treated medically, according to research published in the British Journal of Ophthalmology.

In a study from Investigative Ophthalmology & Vision Science, researchers were unable to draw any association between therapeutic lowering of intraocular pressure and improvement in the visual field in treatment-naïve glaucoma patients from the Early Manifest Glaucoma Trial cohort.

ANAHEIM, Calif. – Cyclosporine use reduced tear osmolarity and corneal and conjunctival staining and increased contact lens wearing time in patients who had tear hyperosmolarity, according to a poster presented here at the American Academy of Optometry meeting.

ANAHEIM, Calif. – Allergan has received FDA approval for a multidose form of Restasis (cyclosporine ophthalmic emulsion 0.05%), Mark Dunbar, OD, reported.

Researchers determined that adding ripasudil to patients’ already-maximum therapeutic regimens may lower IOP significantly and also prevent the need for glaucoma surgery.

In the months since implementing dropless cataract surgery, the patients and physicians in our practice have enjoyed considerable advantages to this approach.

Researchers found that hyaluronic acid-trehalose is safe and offers greater patient satisfaction than existing HA-only eye drops, particularly for the first month of treatment, in patients with moderate to severe dry eye disease.